Crossmark

News in diagnosis, treatment, and risk group assessment

Crossref DOI link: https://doi.org/10.1038/nrurol.2016.264

Published Online: 2017-01-04

Published Print: 2017-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zigeuner, Richard
License Information

Text and Data Mining valid from 2017-01-04
More Information

Article History

First Online: 4 January 2017

Competing interests

: The author declares that he has received speaker's honoraria and travel support from Amgen, Astellas, Bayer, GlaxoSmithKline, Ipsen, Novartis, Pfizer, Roche, and Takeda.